US4069316A
(en)
*
|
1976-11-01 |
1978-01-17 |
Takeda Chemical Industries, Ltd. |
Method for producing antibiotic T-42082 and antibiotic T-42082
|
US4230692A
(en)
*
|
1978-11-03 |
1980-10-28 |
Ayerst Mckenna & Harrison, Inc. |
Ravidomycin and process of preparation
|
US5206018A
(en)
*
|
1978-11-03 |
1993-04-27 |
Ayerst, Mckenna & Harrison, Inc. |
Use of rapamycin in treatment of tumors
|
US5066493A
(en)
*
|
1978-11-03 |
1991-11-19 |
American Home Products Corporation |
Rapamycin in treatment of tumors
|
AU543727B2
(en)
|
1980-06-02 |
1985-05-02 |
Ayerst Mckenna & Harrison Inc. |
Injectable composition of rapamycin
|
US4316885A
(en)
*
|
1980-08-25 |
1982-02-23 |
Ayerst, Mckenna And Harrison, Inc. |
Acyl derivatives of rapamycin
|
US4401653A
(en)
*
|
1981-03-09 |
1983-08-30 |
Ayerst, Mckenna & Harrison Inc. |
Combination of rapamycin and picibanil for the treatment of tumors
|
US4375464A
(en)
*
|
1981-11-19 |
1983-03-01 |
Ayerst, Mckenna & Harrison Inc. |
Antibiotic AY24,668 and process of preparation
|
AR240943A1
(es)
*
|
1985-02-05 |
1991-03-27 |
Sankio Company Limited |
Nuevo compuesto agroquimico denominado "sustancia n*51262" procedimiento para prepararlo y composicion que lo comprende"
|
US5100899A
(en)
*
|
1989-06-06 |
1992-03-31 |
Roy Calne |
Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
|
US5120726A
(en)
*
|
1991-03-08 |
1992-06-09 |
American Home Products Corporation |
Rapamycin hydrazones
|
US5023264A
(en)
*
|
1990-07-16 |
1991-06-11 |
American Home Products Corporation |
Rapamycin oximes
|
US5023263A
(en)
*
|
1990-08-09 |
1991-06-11 |
American Home Products Corporation |
42-oxorapamycin
|
US5023262A
(en)
*
|
1990-08-14 |
1991-06-11 |
American Home Products Corporation |
Hydrogenated rapamycin derivatives
|
US5378696A
(en)
*
|
1990-09-19 |
1995-01-03 |
American Home Products Corporation |
Rapamycin esters
|
US5358944A
(en)
*
|
1990-09-19 |
1994-10-25 |
American Home Products Corporation |
Rapamycin esters for treating transplantation rejection
|
US5130307A
(en)
*
|
1990-09-28 |
1992-07-14 |
American Home Products Corporation |
Aminoesters of rapamycin
|
US5221670A
(en)
*
|
1990-09-19 |
1993-06-22 |
American Home Products Corporation |
Rapamycin esters
|
US5233036A
(en)
*
|
1990-10-16 |
1993-08-03 |
American Home Products Corporation |
Rapamycin alkoxyesters
|
US5080899A
(en)
*
|
1991-02-22 |
1992-01-14 |
American Home Products Corporation |
Method of treating pulmonary inflammation
|
US5078999A
(en)
|
1991-02-22 |
1992-01-07 |
American Home Products Corporation |
Method of treating systemic lupus erythematosus
|
US5120842A
(en)
*
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5321009A
(en)
*
|
1991-04-03 |
1994-06-14 |
American Home Products Corporation |
Method of treating diabetes
|
US5100883A
(en)
*
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
*
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5147877A
(en)
*
|
1991-04-18 |
1992-09-15 |
Merck & Co. Inc. |
Semi-synthetic immunosuppressive macrolides
|
US5091389A
(en)
*
|
1991-04-23 |
1992-02-25 |
Merck & Co., Inc. |
Lipophilic macrolide useful as an immunosuppressant
|
US5102876A
(en)
*
|
1991-05-07 |
1992-04-07 |
American Home Products Corporation |
Reduction products of rapamycin
|
US5138051A
(en)
*
|
1991-08-07 |
1992-08-11 |
American Home Products Corporation |
Rapamycin analogs as immunosuppressants and antifungals
|
US5776943A
(en)
*
|
1991-05-14 |
1998-07-07 |
American Home Products Corporation |
Rapamycin metabolites
|
US5118677A
(en)
*
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
US5120727A
(en)
*
|
1991-05-29 |
1992-06-09 |
American Home Products Corporation |
Rapamycin dimers
|
US5120725A
(en)
*
|
1991-05-29 |
1992-06-09 |
American Home Products Corporation |
Bicyclic rapamycins
|
SG43072A1
(en)
|
1991-06-18 |
1997-10-17 |
American Home Prod |
Method of treating adult t-cell leukemia/lymphoma
|
IL102414A
(en)
*
|
1991-07-25 |
1996-08-04 |
Univ Louisville Res Found |
Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
|
US5162333A
(en)
*
|
1991-09-11 |
1992-11-10 |
American Home Products Corporation |
Aminodiesters of rapamycin
|
US5286730A
(en)
*
|
1991-09-17 |
1994-02-15 |
American Home Products Corporation |
Method of treating immunoinflammatory disease
|
US5286731A
(en)
*
|
1991-09-17 |
1994-02-15 |
American Home Products Corporation |
Method of treating immunoinflammatory bowel disease
|
US5151413A
(en)
*
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
US5164399A
(en)
*
|
1991-11-18 |
1992-11-17 |
American Home Products Corporation |
Rapamycin pyrazoles
|
US5516781A
(en)
*
|
1992-01-09 |
1996-05-14 |
American Home Products Corporation |
Method of treating restenosis with rapamycin
|
US5221740A
(en)
*
|
1992-01-16 |
1993-06-22 |
American Home Products Corporation |
Oxepane isomers of rapamycin useful as immunosuppressive agents
|
US5262424A
(en)
*
|
1992-02-18 |
1993-11-16 |
American Home Products Corporation |
Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
|
US5177203A
(en)
*
|
1992-03-05 |
1993-01-05 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
|
DE69302945T2
(de)
|
1992-03-27 |
1996-10-10 |
American Home Prod |
29-Demethoxyrapamycin zur Induktion der Immunosuppression
|
EP0633783B1
(en)
*
|
1992-03-30 |
2000-06-07 |
American Home Products Corporation |
Rapamycin formulation for iv injection
|
US5288711A
(en)
*
|
1992-04-28 |
1994-02-22 |
American Home Products Corporation |
Method of treating hyperproliferative vascular disease
|
US5256790A
(en)
*
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
CA2106034A1
(en)
*
|
1992-09-24 |
1994-03-25 |
Ralph J. Russo |
21-norrapamycin
|
US5318895A
(en)
*
|
1992-10-05 |
1994-06-07 |
Merck & Co., Inc. |
Aspergillus niger mutants
|
US5302584A
(en)
*
|
1992-10-13 |
1994-04-12 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480988A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5434260A
(en)
*
|
1992-10-13 |
1995-07-18 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5489680A
(en)
*
|
1992-10-13 |
1996-02-06 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480989A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5262423A
(en)
*
|
1992-10-29 |
1993-11-16 |
American Home Products Corporation |
Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
|
US5258389A
(en)
*
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
US5260300A
(en)
*
|
1992-11-19 |
1993-11-09 |
American Home Products Corporation |
Rapamycin carbonate esters as immuno-suppressant agents
|
US5482945A
(en)
*
|
1992-12-22 |
1996-01-09 |
American Home Products Corporation |
Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
|
US5349060A
(en)
*
|
1993-01-07 |
1994-09-20 |
American Home Products Corporation |
Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
|
GB9302569D0
(en)
*
|
1993-02-10 |
1993-03-24 |
Smithkline Beecham Plc |
Novel compound
|
US5252579A
(en)
*
|
1993-02-16 |
1993-10-12 |
American Home Products Corporation |
Macrocyclic immunomodulators
|
US5310901A
(en)
*
|
1993-03-05 |
1994-05-10 |
Merck & Co., Inc. |
O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
|
US5310903A
(en)
*
|
1993-03-05 |
1994-05-10 |
Merck & Co., Inc. |
Imidazolidyl rapamycin derivatives
|
US7279561B1
(en)
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
ES2176245T3
(es)
|
1993-04-23 |
2002-12-01 |
Wyeth Corp |
Anticuerpos de ramapicinas de ciclo abierto.
|
US5504091A
(en)
*
|
1993-04-23 |
1996-04-02 |
American Home Products Corporation |
Biotin esters of rapamycin
|
CH686761A5
(de)
*
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
AT408520B
(de)
*
|
1993-05-27 |
2001-12-27 |
Novartis Erfind Verwalt Gmbh |
Galenische formulierungen
|
GB9315914D0
(en)
*
|
1993-07-31 |
1993-09-15 |
Smithkline Beecham Plc |
Novel compound
|
US5387680A
(en)
*
|
1993-08-10 |
1995-02-07 |
American Home Products Corporation |
C-22 ring stabilized rapamycin derivatives
|
IL111004A
(en)
*
|
1993-09-30 |
1998-06-15 |
American Home Prod |
Oral formulations of rapamycin
|
US5516770A
(en)
*
|
1993-09-30 |
1996-05-14 |
American Home Products Corporation |
Rapamycin formulation for IV injection
|
US5536729A
(en)
*
|
1993-09-30 |
1996-07-16 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
US5616588A
(en)
*
|
1993-09-30 |
1997-04-01 |
American Home Products Corporation |
Rapamycin formulation for IV injection
|
US5391730A
(en)
*
|
1993-10-08 |
1995-02-21 |
American Home Products Corporation |
Phosphorylcarbamates of rapamycin and oxime derivatives thereof
|
US5373014A
(en)
*
|
1993-10-08 |
1994-12-13 |
American Home Products Corporation |
Rapamycin oximes
|
US5378836A
(en)
*
|
1993-10-08 |
1995-01-03 |
American Home Products Corporation |
Rapamycin oximes and hydrazones
|
CA2175215C
(en)
*
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
US5527907A
(en)
*
|
1993-11-19 |
1996-06-18 |
Abbott Laboratories |
Macrolide immunomodulators
|
US5385909A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Heterocyclic esters of rapamycin
|
US5385910A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Gem-distributed esters of rapamycin
|
US5385908A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Hindered esters of rapamycin
|
US5389639A
(en)
*
|
1993-12-29 |
1995-02-14 |
American Home Products Company |
Amino alkanoic esters of rapamycin
|
US5525610A
(en)
*
|
1994-03-31 |
1996-06-11 |
American Home Products Corporation |
42-Epi-rapamycin and pharmaceutical compositions thereof
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
US6150137A
(en)
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
US5463048A
(en)
*
|
1994-06-14 |
1995-10-31 |
American Home Products Corporation |
Rapamycin amidino carbamates
|
WO1996006847A1
(en)
*
|
1994-08-31 |
1996-03-07 |
Pfizer Inc. |
Process for preparing demethylrapamycins
|
MY129435A
(en)
|
1994-10-26 |
2007-04-30 |
Novartis Ag |
Pharmaceutical microemulsion preconcentrates
|
US5491231A
(en)
*
|
1994-11-28 |
1996-02-13 |
American Home Products Corporation |
Hindered N-oxide esters of rapamycin
|
US5563145A
(en)
*
|
1994-12-07 |
1996-10-08 |
American Home Products Corporation |
Rapamycin 42-oximes and hydroxylamines
|
US5561138A
(en)
*
|
1994-12-13 |
1996-10-01 |
American Home Products Corporation |
Method of treating anemia
|
US5606222A
(en)
*
|
1994-12-29 |
1997-02-25 |
Philips Electronics North America Corporation |
Lighting system with a device for reducing system wattage
|
US5496832A
(en)
*
|
1995-03-09 |
1996-03-05 |
American Home Products Corporation |
Method of treating cardiac inflammatory disease
|
FR2736550B1
(fr)
*
|
1995-07-14 |
1998-07-24 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
|
US5780462A
(en)
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
US7282220B1
(en)
|
1996-11-05 |
2007-10-16 |
Hsing-Wen Sung |
Genipin-crosslinked gelatin microspheres as drug carrier
|
US5989591A
(en)
*
|
1997-03-14 |
1999-11-23 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
US6273913B1
(en)
*
|
1997-04-18 |
2001-08-14 |
Cordis Corporation |
Modified stent useful for delivery of drugs along stent strut
|
US5985325A
(en)
*
|
1997-06-13 |
1999-11-16 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US20060198867A1
(en)
*
|
1997-09-25 |
2006-09-07 |
Abbott Laboratories, Inc. |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
US6890546B2
(en)
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US6015815A
(en)
*
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
US20030129215A1
(en)
*
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
US7357942B2
(en)
*
|
1997-09-26 |
2008-04-15 |
Abbott Laboratories |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
|
US8257725B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US8394398B2
(en)
*
|
1997-09-26 |
2013-03-12 |
Abbott Laboratories |
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
|
US8057816B2
(en)
*
|
1997-09-26 |
2011-11-15 |
Abbott Laboratories |
Compositions and methods of administering paclitaxel with other drugs using medical devices
|
US7378105B2
(en)
*
|
1997-09-26 |
2008-05-27 |
Abbott Laboratories |
Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
|
US8257726B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
|
BR9814615A
(pt)
|
1997-10-22 |
2001-10-16 |
Jens Ponikau |
Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa
|
US20030216303A1
(en)
*
|
1998-03-06 |
2003-11-20 |
Michael Ambuhl |
Emulsion preconcentrates containing cyclosporin or a macrolide
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
US20060240070A1
(en)
*
|
1998-09-24 |
2006-10-26 |
Cromack Keith R |
Delivery of highly lipophilic agents via medical devices
|
US8257724B2
(en)
*
|
1998-09-24 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US7960405B2
(en)
*
|
1998-09-24 |
2011-06-14 |
Abbott Laboratories |
Compounds and methods for treatment and prevention of diseases
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
GB9826882D0
(en)
*
|
1998-12-07 |
1999-01-27 |
Novartis Ag |
Organic compounds
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
US6790228B2
(en)
*
|
1999-12-23 |
2004-09-14 |
Advanced Cardiovascular Systems, Inc. |
Coating for implantable devices and a method of forming the same
|
US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US7807211B2
(en)
|
1999-09-03 |
2010-10-05 |
Advanced Cardiovascular Systems, Inc. |
Thermal treatment of an implantable medical device
|
GB0008785D0
(en)
|
2000-04-10 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
US6573074B2
(en)
|
2000-04-12 |
2003-06-03 |
Smithkline Beecham Plc |
Methods for ansamitocin production
|
US7300662B2
(en)
|
2000-05-12 |
2007-11-27 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US7419678B2
(en)
*
|
2000-05-12 |
2008-09-02 |
Cordis Corporation |
Coated medical devices for the prevention and treatment of vascular disease
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US6670355B2
(en)
*
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
AU2001290841A1
(en)
|
2000-09-19 |
2002-04-02 |
American Home Products Corporation |
Water soluble rapamycin esters
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
US20060222756A1
(en)
*
|
2000-09-29 |
2006-10-05 |
Cordis Corporation |
Medical devices, drug coatings and methods of maintaining the drug coatings thereon
|
US7261735B2
(en)
*
|
2001-05-07 |
2007-08-28 |
Cordis Corporation |
Local drug delivery devices and methods for maintaining the drug coatings thereon
|
AU2001294869B2
(en)
|
2000-09-29 |
2006-06-15 |
Cardinal Health 529, Llc |
Coated medical devices
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
US8182527B2
(en)
|
2001-05-07 |
2012-05-22 |
Cordis Corporation |
Heparin barrier coating for controlled drug release
|
US20020198137A1
(en)
*
|
2001-06-01 |
2002-12-26 |
Wyeth |
Antineoplastic combinations
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
BR0211905A
(pt)
|
2001-08-22 |
2004-09-21 |
Wyeth Corp |
Dialdeìdos de rapamicina
|
BR0211986A
(pt)
|
2001-08-22 |
2004-09-28 |
Wyeth Corp |
29-enóis de rapamicina
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
US7195640B2
(en)
|
2001-09-25 |
2007-03-27 |
Cordis Corporation |
Coated medical devices for the treatment of vulnerable plaque
|
US20030065377A1
(en)
|
2001-09-28 |
2003-04-03 |
Davila Luis A. |
Coated medical devices
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US6939376B2
(en)
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
PL369671A1
(en)
*
|
2002-01-10 |
2005-05-02 |
Novartis Ag |
Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US20030204168A1
(en)
*
|
2002-04-30 |
2003-10-30 |
Gjalt Bosma |
Coated vascular devices
|
US20070083258A1
(en)
|
2005-10-06 |
2007-04-12 |
Robert Falotico |
Intraluminal device and therapeutic agent combination for treating aneurysmal disease
|
DE60315723T2
(de)
|
2002-07-16 |
2008-06-19 |
Biotica Technology Ltd. |
Herstellung von Polyketiden und anderen natürlichen Produkten
|
SI1553940T1
(sl)
*
|
2002-07-30 |
2008-08-31 |
Wyeth Corp |
Parenteralne farmacevtske oblike, ki vsebujejo rapamicin-hidroksiester
|
PL375698A1
(en)
|
2002-09-06 |
2005-12-12 |
Abbott Laboratories |
Medical device having hydration inhibitor
|
AU2002330737A1
(en)
*
|
2002-09-09 |
2004-03-29 |
Biocon Limited |
Solid state fermentation and fed batch for the production of an immunosuppressant
|
PT1635830E
(pt)
*
|
2002-09-17 |
2008-12-31 |
Wyeth Corp |
Formulação granulada do éster de rapamicina cci-779
|
US6919100B2
(en)
*
|
2003-01-22 |
2005-07-19 |
Cordis Corporation |
Method for coating medical devices
|
US20050038504A1
(en)
*
|
2003-01-22 |
2005-02-17 |
Harry Halleriet |
Kit for applying drug coating to a medical device in surgeon room
|
US8318235B2
(en)
*
|
2003-01-22 |
2012-11-27 |
Cordis Corporation |
Method for applying drug coating to a medical device in surgeon room
|
AR042938A1
(es)
*
|
2003-02-06 |
2005-07-06 |
Wyeth Corp |
Uso del cci-779 en el tratamiento de la fibrosis hepatica
|
US20040167572A1
(en)
*
|
2003-02-20 |
2004-08-26 |
Roth Noah M. |
Coated medical devices
|
UA83484C2
(uk)
*
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
US7527632B2
(en)
*
|
2003-03-31 |
2009-05-05 |
Cordis Corporation |
Modified delivery device for coated medical devices
|
PT1615640E
(pt)
*
|
2003-04-22 |
2007-04-30 |
Wyeth Corp |
Combinações antineoplásticas
|
WO2004100868A2
(en)
*
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
US7160867B2
(en)
|
2003-05-16 |
2007-01-09 |
Isotechnika, Inc. |
Rapamycin carbohydrate derivatives
|
US20040236416A1
(en)
*
|
2003-05-20 |
2004-11-25 |
Robert Falotico |
Increased biocompatibility of implantable medical devices
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
US20050033417A1
(en)
|
2003-07-31 |
2005-02-10 |
John Borges |
Coating for controlled release of a therapeutic agent
|
US20050137677A1
(en)
|
2003-12-17 |
2005-06-23 |
Rush Scott L. |
Endovascular graft with differentiable porosity along its length
|
US20050249776A1
(en)
*
|
2003-12-19 |
2005-11-10 |
Chen Chao C |
Coated aneurysmal repair device
|
US8747881B2
(en)
|
2003-12-19 |
2014-06-10 |
Cordis Corporation |
Intraluminal medical devices in combination with therapeutic agents
|
US8652502B2
(en)
*
|
2003-12-19 |
2014-02-18 |
Cordis Corporation |
Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
|
DE602004011398T2
(de)
*
|
2004-01-08 |
2009-01-15 |
Wyeth |
Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
|
US7303758B2
(en)
|
2004-01-20 |
2007-12-04 |
Cordis Corporation |
Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
|
US7806924B2
(en)
|
2004-02-18 |
2010-10-05 |
Cordis Corporation |
Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
|
US20050187608A1
(en)
*
|
2004-02-24 |
2005-08-25 |
O'hara Michael D. |
Radioprotective compound coating for medical devices
|
EP1568394A1
(en)
|
2004-02-26 |
2005-08-31 |
Muijs van de Moer, Wouter Matthijs |
Coated electrode
|
US8828416B2
(en)
|
2004-03-09 |
2014-09-09 |
Cordis Corporation |
Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
|
US8431145B2
(en)
|
2004-03-19 |
2013-04-30 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
JP4949227B2
(ja)
*
|
2004-03-19 |
2012-06-06 |
アボット・ラボラトリーズ |
バルーンおよびプロテーゼからの多剤送達
|
US7695731B2
(en)
|
2004-03-22 |
2010-04-13 |
Cordis Corporation |
Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
|
US7875282B2
(en)
*
|
2004-03-22 |
2011-01-25 |
Cordis Corporation |
Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury
|
US7846940B2
(en)
*
|
2004-03-31 |
2010-12-07 |
Cordis Corporation |
Solution formulations of sirolimus and its analogs for CAD treatment
|
US8003122B2
(en)
*
|
2004-03-31 |
2011-08-23 |
Cordis Corporation |
Device for local and/or regional delivery employing liquid formulations of therapeutic agents
|
US7989490B2
(en)
|
2004-06-02 |
2011-08-02 |
Cordis Corporation |
Injectable formulations of taxanes for cad treatment
|
US7704725B2
(en)
*
|
2004-04-12 |
2010-04-27 |
Biocon Limited |
Process for the production of macrolides using a novel strain, Streptomyces sp. BICC 7522
|
US8007737B2
(en)
|
2004-04-14 |
2011-08-30 |
Wyeth |
Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
|
AU2005233612A1
(en)
|
2004-04-14 |
2005-10-27 |
Wyeth |
Proline CCI-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline CCI-779 and CCI-779 using microbial lipase
|
CA2562952A1
(en)
|
2004-04-14 |
2005-11-10 |
Wyeth |
Regiospecific synthesis of rapamycin 42-ester derivatives
|
DE602005010228D1
(de)
*
|
2004-04-14 |
2008-11-20 |
Wyeth Corp |
Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
|
US20050232965A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Robert Falotico |
Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
|
CA2562164A1
(en)
*
|
2004-04-27 |
2005-11-10 |
Wyeth |
Labeling of rapamycin using rapamycin-specific methylases
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
AR050374A1
(es)
*
|
2004-08-20 |
2006-10-18 |
Wyeth Corp |
Forma polimorfica de rafampicina
|
JP5117190B2
(ja)
*
|
2004-08-27 |
2013-01-09 |
コーディス・コーポレイション |
溶媒を含有しない非晶質ラパマイシン
|
WO2006031664A1
(en)
*
|
2004-09-10 |
2006-03-23 |
Ivax Pharmaceuticals S.R.O. |
Process for isolation of crystalline tacrolimus
|
WO2006031661A2
(en)
*
|
2004-09-10 |
2006-03-23 |
Ivax Pharmaceuticals S.R.O. |
Process for isolation of macrolide compounds
|
JP2008513388A
(ja)
*
|
2004-09-16 |
2008-05-01 |
バイエル・ヘルスケア・アクチェンゲゼルシャフト |
動物の皮膚病を処置するための皮膚投与可能な製剤
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
CN101076319A
(zh)
*
|
2004-09-29 |
2007-11-21 |
科迪斯公司 |
稳定的非晶形雷帕霉素样化合物的药物剂型
|
US20060129225A1
(en)
*
|
2004-12-15 |
2006-06-15 |
Kopia Gregory A |
Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium
|
GB0503936D0
(en)
*
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
EP1877004A4
(en)
|
2005-03-23 |
2012-01-25 |
Abbott Lab |
COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF RAPAMYCIN ANALOGUES WITH MEDICAL DEVICES FOR LONG-TERM EFFECT
|
JP5271697B2
(ja)
*
|
2005-03-23 |
2013-08-21 |
アボット ラボラトリーズ |
医療装置を介する高親油性薬剤の送達
|
KR101492545B1
(ko)
*
|
2005-07-15 |
2015-02-12 |
미셀 테크놀로지즈, 인코포레이티드 |
제어된 형태의 약물 분말을 함유하는 중합체 코팅
|
JP5756588B2
(ja)
*
|
2005-07-15 |
2015-07-29 |
ミセル テクノロジーズ、インコーポレイテッド |
制御されたモルホロジーの薬剤粉末を含むポリマーコーティング
|
US20090062909A1
(en)
|
2005-07-15 |
2009-03-05 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
EP2586798A3
(en)
|
2005-07-25 |
2013-08-07 |
Emergent Product Development Seattle, LLC |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
US20070026042A1
(en)
*
|
2005-07-29 |
2007-02-01 |
Narayanan Pallasssana V |
System for treating aneurysmal disease
|
US20070048350A1
(en)
*
|
2005-08-31 |
2007-03-01 |
Robert Falotico |
Antithrombotic coating for drug eluting medical devices
|
US20090246212A1
(en)
*
|
2005-09-30 |
2009-10-01 |
Kyoto University |
Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic
|
US8784860B2
(en)
*
|
2005-10-27 |
2014-07-22 |
Cordis Corporation |
Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
|
US20070173787A1
(en)
*
|
2005-11-01 |
2007-07-26 |
Huang Mark C T |
Thin-film nitinol based drug eluting stent
|
US20070116736A1
(en)
|
2005-11-23 |
2007-05-24 |
Argentieri Dennis C |
Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
|
US20070128242A1
(en)
*
|
2005-12-01 |
2007-06-07 |
Zhao Jonathan Z |
Polymeric compositions for controlled release or delivery of pharmacologically active agents
|
JP2009518648A
(ja)
*
|
2005-12-07 |
2009-05-07 |
ワイス |
結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
|
US7700614B2
(en)
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
US7842312B2
(en)
|
2005-12-29 |
2010-11-30 |
Cordis Corporation |
Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
|
US7678901B2
(en)
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
US20070203169A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Zhao Jonathon Z |
Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
|
US7622477B2
(en)
*
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
PL2019657T3
(pl)
|
2006-04-26 |
2015-10-30 |
Micell Technologies Inc |
Powłoki zawierające wiele leków
|
GB0609963D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
GB0609962D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
AU2007315790A1
(en)
*
|
2006-06-30 |
2008-05-08 |
Interface Biologics, Inc. |
Bioresponsive polymers
|
US8506984B2
(en)
|
2006-07-26 |
2013-08-13 |
Cordis Corporation |
Therapeutic agent elution control process
|
RU2010104916A
(ru)
*
|
2006-08-16 |
2011-08-20 |
Михаил В. Благосклонный (US) |
Способ профилактики и лечения возрастных заболеваний
|
US10695327B2
(en)
|
2006-09-13 |
2020-06-30 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
CN101557814B
(zh)
|
2006-09-13 |
2015-05-20 |
万能医药公司 |
大环内酯化合物及它们的使用方法
|
US8088789B2
(en)
|
2006-09-13 |
2012-01-03 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
WO2008042909A2
(en)
|
2006-10-02 |
2008-04-10 |
Micell Technologies Inc. |
Surgical sutures having increased strength
|
US20080097591A1
(en)
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
EP2081694B1
(en)
|
2006-10-23 |
2020-05-13 |
Micell Technologies, Inc. |
Holder for electrically charging a substrate during coating
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8414909B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8430055B2
(en)
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
US20080138405A1
(en)
*
|
2006-12-06 |
2008-06-12 |
Raheja Praveen |
Sirolimus nanodispersion
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
CN101711137B
(zh)
|
2007-01-08 |
2014-10-22 |
米歇尔技术公司 |
具有可生物降解层的支架
|
EP1952807A1
(en)
*
|
2007-01-24 |
2008-08-06 |
LEK Pharmaceuticals D.D. |
Sirolimus formulation
|
US20090281059A1
(en)
|
2007-02-21 |
2009-11-12 |
Robert Falotico |
Coating for a medical device having an anti-thrombotic conjugate
|
US20080241215A1
(en)
|
2007-03-28 |
2008-10-02 |
Robert Falotico |
Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
|
TW200845960A
(en)
*
|
2007-04-05 |
2008-12-01 |
Wyeth Corp |
Wortmannin-rapalog conjugate and uses thereof
|
CN101815540B
(zh)
|
2007-05-25 |
2015-08-19 |
米歇尔技术公司 |
用于医疗器材涂层的聚合物膜
|
US20090130210A1
(en)
*
|
2007-09-11 |
2009-05-21 |
Raheja Praveen |
Pharmaceutical compositions of sirolimus
|
US20090068266A1
(en)
*
|
2007-09-11 |
2009-03-12 |
Raheja Praveen |
Sirolimus having specific particle size and pharmaceutical compositions thereof
|
US20090074831A1
(en)
*
|
2007-09-18 |
2009-03-19 |
Robert Falotico |
LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
EP2203498B1
(en)
|
2007-10-05 |
2017-12-06 |
Interface Biologics Inc. |
Oligofluorinated cross-linked polymers and uses thereof
|
EP2214748B1
(en)
|
2007-10-19 |
2016-12-07 |
Interface Biologics Inc. |
Self-eliminating coatings
|
WO2009058990A2
(en)
|
2007-10-31 |
2009-05-07 |
Cordis Corporation |
Vascular closure device
|
US9603980B2
(en)
|
2008-02-26 |
2017-03-28 |
CARDINAL HEALTH SWITZERLAND 515 GmbH |
Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices
|
US8420110B2
(en)
|
2008-03-31 |
2013-04-16 |
Cordis Corporation |
Drug coated expandable devices
|
US8409601B2
(en)
|
2008-03-31 |
2013-04-02 |
Cordis Corporation |
Rapamycin coated expandable devices
|
CN102099377A
(zh)
|
2008-04-11 |
2011-06-15 |
新兴产品开发西雅图有限公司 |
Cd37免疫治疗剂及其与双功能化学治疗剂的联合
|
JP5608160B2
(ja)
|
2008-04-17 |
2014-10-15 |
ミセル テクノロジーズ、インコーポレイテッド |
生体吸収性の層を有するステント
|
US8273404B2
(en)
*
|
2008-05-19 |
2012-09-25 |
Cordis Corporation |
Extraction of solvents from drug containing polymer reservoirs
|
TWI527819B
(zh)
|
2008-06-10 |
2016-04-01 |
艾伯維有限公司 |
新穎三環化合物
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
US9486431B2
(en)
|
2008-07-17 |
2016-11-08 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2011009096A1
(en)
|
2009-07-16 |
2011-01-20 |
Micell Technologies, Inc. |
Drug delivery medical device
|
JP2012504654A
(ja)
*
|
2008-10-03 |
2012-02-23 |
エリクシアー メディカル コーポレイション |
多環状ラクトン化合物およびその使用方法
|
US20100098770A1
(en)
*
|
2008-10-16 |
2010-04-22 |
Manikandan Ramalingam |
Sirolimus pharmaceutical formulations
|
US20120064143A1
(en)
|
2008-11-11 |
2012-03-15 |
The Board Of Regents Of The University Of Texas System |
Inhibition of mammalian target of rapamycin
|
SG194404A1
(en)
*
|
2008-12-23 |
2013-11-29 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
US8551973B2
(en)
*
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
US8716262B2
(en)
*
|
2008-12-23 |
2014-05-06 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8834913B2
(en)
|
2008-12-26 |
2014-09-16 |
Battelle Memorial Institute |
Medical implants and methods of making medical implants
|
WO2010086863A2
(en)
*
|
2009-02-02 |
2010-08-05 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Crystalline drug-containing coatings
|
US20100233733A1
(en)
*
|
2009-02-10 |
2010-09-16 |
Nodality, Inc., A Delaware Corporation |
Multiple mechanisms for modulation of the pi3 kinase pathway
|
FR2943539B1
(fr)
|
2009-03-31 |
2011-07-22 |
Ethypharm Sa |
Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
|
WO2010120552A2
(en)
|
2009-04-01 |
2010-10-21 |
Micell Technologies, Inc. |
Coated stents
|
EP2416792A4
(en)
|
2009-04-10 |
2012-10-24 |
Haiyan Qi |
NEW ANTI-AGING APPROACHES AND METHOD FOR IDENTIFYING THEM
|
US20100268187A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Ranbaxy Laboratories Limited |
Packaging for sirolimus and composition thereof
|
WO2010121187A2
(en)
|
2009-04-17 |
2010-10-21 |
Micell Techologies, Inc. |
Stents having controlled elution
|
US20100280600A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Vipul Bhupendra Dave |
Dual drug stent
|
US20110137407A1
(en)
*
|
2009-07-09 |
2011-06-09 |
Thai Minh Nguyen |
Bare metal stent with drug eluting reservoirs
|
US9327060B2
(en)
|
2009-07-09 |
2016-05-03 |
CARDINAL HEALTH SWITZERLAND 515 GmbH |
Rapamycin reservoir eluting stent
|
EA201290255A1
(ru)
|
2009-10-30 |
2013-04-30 |
Ариад Фармасьютикалз, Инк. |
Способы и композиции для лечения рака
|
US10391059B2
(en)
|
2009-11-11 |
2019-08-27 |
Rapamycin Holdings, Inc. |
Oral rapamycin nanoparticle preparations and use
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
JP2013512282A
(ja)
*
|
2009-12-01 |
2013-04-11 |
アボット・ラボラトリーズ |
新規三環式化合物
|
SI2506716T1
(sl)
|
2009-12-01 |
2017-10-30 |
Abb Vie Inc. |
Nove triciklične spojine
|
US8480620B2
(en)
|
2009-12-11 |
2013-07-09 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable solubility profile for drug-coated balloon
|
US8951595B2
(en)
|
2009-12-11 |
2015-02-10 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable molecular architecture for drug-coated balloon
|
US11369498B2
(en)
|
2010-02-02 |
2022-06-28 |
MT Acquisition Holdings LLC |
Stent and stent delivery system with improved deliverability
|
WO2011128910A2
(en)
|
2010-03-02 |
2011-10-20 |
Rpg Life Sciences Limited |
A drug delivery solid dosage formulation of sirolimus
|
US8795762B2
(en)
|
2010-03-26 |
2014-08-05 |
Battelle Memorial Institute |
System and method for enhanced electrostatic deposition and surface coatings
|
CN104017020B
(zh)
|
2010-03-31 |
2017-04-12 |
吉利德制药有限责任公司 |
核苷氨基磷酸酯
|
US10232092B2
(en)
|
2010-04-22 |
2019-03-19 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
WO2012009684A2
(en)
|
2010-07-16 |
2012-01-19 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US20120130481A1
(en)
|
2010-11-18 |
2012-05-24 |
Robert Falotico |
Local vascular delivery of adenosine a2a receptor agonists in combination with other agents to reduce myocardial injury
|
US20120303115A1
(en)
|
2011-05-25 |
2012-11-29 |
Dadino Ronald C |
Expandable devices coated with a rapamycin composition
|
US20120302954A1
(en)
|
2011-05-25 |
2012-11-29 |
Zhao Jonathon Z |
Expandable devices coated with a paclitaxel composition
|
WO2012166819A1
(en)
|
2011-05-31 |
2012-12-06 |
Micell Technologies, Inc. |
System and process for formation of a time-released, drug-eluting transferable coating
|
EP2532740A1
(en)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
|
CA2841360A1
(en)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
CN102372726B
(zh)
*
|
2011-11-08 |
2014-02-19 |
福建省微生物研究所 |
西罗莫司粗晶的制备方法
|
CN102433364B
(zh)
*
|
2011-11-10 |
2013-10-23 |
中科医药行业生产力促进中心有限公司 |
一种微生物发酵法制取雷帕霉素的工艺
|
EP2594260A1
(en)
|
2011-11-18 |
2013-05-22 |
LEK Pharmaceuticals d.d. |
Solid preparations comprising sirolimus with desired bioavailability and method for its preparation
|
KR20140107413A
(ko)
|
2011-12-16 |
2014-09-04 |
화이자 인코포레이티드 |
암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
US9365880B2
(en)
|
2012-04-12 |
2016-06-14 |
Natco Pharma Limited |
Fermentation process for the production of rapamycin
|
DK2859001T3
(da)
|
2012-06-08 |
2016-05-30 |
Biotronik Ag |
Rapamycin 40-o-cyklisk kulbrinteestere, sammensætninger og fremgangsmåder
|
US9278090B2
(en)
|
2012-09-05 |
2016-03-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preventing the development of mucositis and related disorders
|
WO2014068070A1
(en)
|
2012-10-31 |
2014-05-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
WO2014072984A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Improved process for isolation and purification of rapamycin from fermentation broth
|
EP2919759A4
(en)
|
2012-11-14 |
2016-07-20 |
Ohio State Innovation Foundation |
MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
|
WO2014165264A1
(en)
|
2013-03-12 |
2014-10-09 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
US20160030401A1
(en)
|
2013-03-13 |
2016-02-04 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
|
AU2014265460B2
(en)
|
2013-05-15 |
2018-10-18 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
CA2926719C
(en)
|
2013-10-08 |
2020-11-24 |
Lam Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
TWI679976B
(zh)
|
2013-11-13 |
2019-12-21 |
瑞士商諾華公司 |
低及免疫增強劑量之mtor抑制劑及其用途
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
CN106573067A
(zh)
|
2014-02-11 |
2017-04-19 |
拉姆医疗公司 |
用于淋巴管平滑肌瘤病治疗的雷帕霉素
|
US10307371B2
(en)
|
2014-02-11 |
2019-06-04 |
AI Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
US20170081411A1
(en)
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
EP3125875B1
(en)
|
2014-04-04 |
2023-06-07 |
AI Therapeutics, Inc. |
An inhalable rapamycin formulation for treating age-related conditions
|
CN107075482B
(zh)
|
2014-04-07 |
2021-03-16 |
诺华股份有限公司 |
使用抗cd19嵌合抗原受体治疗癌症
|
CA2955386A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
CN107108744B
(zh)
|
2014-08-19 |
2020-09-25 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
WO2016040806A1
(en)
|
2014-09-11 |
2016-03-17 |
The Regents Of The University Of California |
mTORC1 INHIBITORS
|
EP3967709A1
(en)
|
2014-09-17 |
2022-03-16 |
Novartis AG |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CA2963085C
(en)
|
2014-10-07 |
2023-02-21 |
Lam Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
WO2016057705A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
WO2016069556A2
(en)
|
2014-10-29 |
2016-05-06 |
University Of Maryland |
Methods of treating age-related symptoms in mammals and compositions therefor
|
MA40910A
(fr)
|
2014-11-07 |
2017-09-12 |
Civitas Therapeutics Inc |
Poudres de rapamycine pour administration pulmonaire
|
WO2016098078A2
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Dimerization switches and uses thereof
|
WO2016130645A1
(en)
|
2015-02-10 |
2016-08-18 |
Lam Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
EP3280795B1
(en)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
CN104844620B
(zh)
*
|
2015-04-10 |
2018-06-19 |
鲁南新时代生物技术有限公司 |
一种雷帕霉素的分离纯化方法
|
EP3283619B1
(en)
|
2015-04-17 |
2023-04-05 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
AU2016263176A1
(en)
|
2015-05-20 |
2017-12-07 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
US20180258100A1
(en)
*
|
2015-08-28 |
2018-09-13 |
Matthew Alan Gregory |
RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11773106B2
(en)
|
2015-10-16 |
2023-10-03 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
EP3362455A1
(en)
|
2015-10-16 |
2018-08-22 |
AbbVie Inc. |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
EP3373927A1
(en)
|
2015-11-11 |
2018-09-19 |
Novartis AG |
Uses of myostatin antagonists, combinations containing them and uses thereof
|
CN116769050A
(zh)
|
2016-07-20 |
2023-09-19 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
WO2018096402A1
(en)
|
2016-11-23 |
2018-05-31 |
Novartis Ag |
Methods of enhancing immune response with everolimus, dactolisib or both
|
AU2018219317A1
(en)
|
2017-02-10 |
2019-09-26 |
Mount Tam Therapeutics, Inc. |
Rapamycin analog
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
EP3644997A1
(en)
|
2017-06-26 |
2020-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of olmsted syndrome
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
EP3788049B1
(en)
|
2018-05-01 |
2023-03-29 |
Revolution Medicines, Inc. |
C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
|
KR20210018243A
(ko)
|
2018-05-01 |
2021-02-17 |
레볼루션 메디슨즈, 인크. |
mTOR 억제제로서의 C26-연결된 라파마이신 유사체
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
EP3826650A4
(en)
|
2018-07-23 |
2022-07-27 |
Enclear Therapies, Inc. |
METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
|
WO2020023417A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
EP3849545A1
(en)
|
2018-09-10 |
2021-07-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of neurofibromatosis
|
CN113260619A
(zh)
|
2018-12-18 |
2021-08-13 |
诺华股份有限公司 |
雷帕霉素衍生物
|
KR20210142689A
(ko)
|
2019-03-26 |
2021-11-25 |
노파르티스 아게 |
이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도
|
EP3952947A1
(en)
|
2019-04-11 |
2022-02-16 |
Enclear Therapies, Inc. |
Methods of amelioration of cerebrospinal fluid and devices and systems therefor
|
US20220409567A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Thomas Winston |
Adjuvant and complementary therapies for the treatment of cancer
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|